BR112022020444A2 - Composições e métodos para o tratamento de distúrbios de agregação de proteínas - Google Patents
Composições e métodos para o tratamento de distúrbios de agregação de proteínasInfo
- Publication number
- BR112022020444A2 BR112022020444A2 BR112022020444A BR112022020444A BR112022020444A2 BR 112022020444 A2 BR112022020444 A2 BR 112022020444A2 BR 112022020444 A BR112022020444 A BR 112022020444A BR 112022020444 A BR112022020444 A BR 112022020444A BR 112022020444 A2 BR112022020444 A2 BR 112022020444A2
- Authority
- BR
- Brazil
- Prior art keywords
- protein aggregation
- compositions
- treatment
- methods
- aggregation disorders
- Prior art date
Links
- 230000004845 protein aggregation Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 abstract 1
- 108010006519 Molecular Chaperones Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 229920000155 polyglutamine Polymers 0.000 abstract 1
- 108010040003 polyglutamine Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063008251P | 2020-04-10 | 2020-04-10 | |
| PCT/US2021/026633 WO2021207636A2 (en) | 2020-04-10 | 2021-04-09 | Compositions and methods for the treatment of protein aggregation disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022020444A2 true BR112022020444A2 (pt) | 2022-11-29 |
Family
ID=75747121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022020444A BR112022020444A2 (pt) | 2020-04-10 | 2021-04-09 | Composições e métodos para o tratamento de distúrbios de agregação de proteínas |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230226223A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4132955A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023520927A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220167324A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115667289A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021254272A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022020444A2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022012525A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202204383A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021207636A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114057858B (zh) | 2020-08-10 | 2023-03-21 | 上海瑞吉康生物医药有限公司 | 对引起神经变性和神经退行性疾病的蛋白聚集具有解聚作用的多肽 |
| AU2021367952A1 (en) * | 2020-10-26 | 2023-06-08 | Sola Biosciences Llc | Compositions and methods for the treatment of alzheimer's disease |
| EP4686478A1 (en) * | 2024-07-31 | 2026-02-04 | Consejo Superior de Investigaciones Científicas (CSIC) | Qbp1 for use in the treatment and/or prevention of type 2 diabetes |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8918616D0 (en) | 1989-08-15 | 1989-09-27 | Univ Glasgow | Herpes simplex virus type 1 mutant |
| US5804413A (en) | 1992-07-31 | 1998-09-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
| GB9415319D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | HSV viral vector |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| EP1002119A1 (en) | 1997-07-31 | 2000-05-24 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Targeted hsv vectors |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| DE69939169D1 (de) | 1998-05-28 | 2008-09-04 | Us Gov Health & Human Serv | Aav5 vektoren und deren verwendung |
| US7465583B2 (en) | 2000-06-01 | 2008-12-16 | The University Of North Carolina At Chapel Hill | Duplexed parvovirus vectors |
| WO2002053703A2 (en) | 2001-01-05 | 2002-07-11 | Children's Hospital, Inc. | Aav2 vectors and methods |
| CN103589692B (zh) | 2001-11-13 | 2018-07-24 | 宾夕法尼亚大学托管会 | 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法 |
| DK2359869T3 (en) | 2001-12-17 | 2019-04-15 | Univ Pennsylvania | Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof |
| EP1668143B1 (en) | 2003-09-30 | 2013-03-20 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor |
| EP1828390B1 (en) | 2004-12-15 | 2012-06-13 | The University Of North Carolina At Chapel Hill | Chimeric vectors |
| JP2008125455A (ja) * | 2006-11-22 | 2008-06-05 | Sapporo Medical Univ | ポリグルタミン凝集体形成阻害活性を有するポリペプチド |
| US20100016221A1 (en) * | 2008-07-17 | 2010-01-21 | Riken | Method of degrading protein by chaperone-mediated autophagy |
| EP2396343B1 (en) | 2009-02-11 | 2017-05-17 | The University of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
| US9169494B2 (en) | 2010-01-12 | 2015-10-27 | The University Of North Carolina At Chapel Hill | Restrictive inverted terminal repeats for viral vectors |
| WO2011097456A2 (en) | 2010-02-05 | 2011-08-11 | The University Of North Carolina At Chapel Hill | Compositions and methods for enhanced parvovirus transduction |
| WO2011140315A2 (en) * | 2010-05-05 | 2011-11-10 | Northwestern University | Method of reducing proteins misfolding and/or aggregation |
| WO2014053879A1 (en) | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| EP2929045B1 (en) * | 2012-12-05 | 2020-12-02 | SOLA Biosciences LLC | Protein expression enhancing polypeptides |
| WO2018058088A1 (en) * | 2016-09-26 | 2018-03-29 | SOLA Biosciences, LLC | Cell-associated secretion-enhancing fusion proteins |
-
2021
- 2021-04-09 JP JP2022561477A patent/JP2023520927A/ja active Pending
- 2021-04-09 EP EP21722705.7A patent/EP4132955A2/en active Pending
- 2021-04-09 MX MX2022012525A patent/MX2022012525A/es unknown
- 2021-04-09 AU AU2021254272A patent/AU2021254272A1/en active Pending
- 2021-04-09 CN CN202180041478.7A patent/CN115667289A/zh active Pending
- 2021-04-09 WO PCT/US2021/026633 patent/WO2021207636A2/en not_active Ceased
- 2021-04-09 TW TW110112984A patent/TW202204383A/zh unknown
- 2021-04-09 BR BR112022020444A patent/BR112022020444A2/pt unknown
- 2021-04-09 US US17/995,901 patent/US20230226223A1/en active Pending
- 2021-04-09 KR KR1020227039402A patent/KR20220167324A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115667289A (zh) | 2023-01-31 |
| MX2022012525A (es) | 2023-02-22 |
| JP2023520927A (ja) | 2023-05-22 |
| KR20220167324A (ko) | 2022-12-20 |
| WO2021207636A3 (en) | 2021-11-18 |
| WO2021207636A2 (en) | 2021-10-14 |
| US20230226223A1 (en) | 2023-07-20 |
| AU2021254272A1 (en) | 2022-10-27 |
| TW202204383A (zh) | 2022-02-01 |
| EP4132955A2 (en) | 2023-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022021604A2 (pt) | Composições e métodos para tratamento de proteinopatias associadas à tdp-43 | |
| CL2020002012A1 (es) | Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas. (divisional solicitud 201903032) | |
| EA202190999A1 (ru) | Композиции на основе полипептидов, стабилизированных с помощью дисульфидной связи, и способы применения | |
| BR112022021823A2 (pt) | Métodos para tratar doenças associadas à mielina e doenças associadas à mitocôndria | |
| MY207132A (en) | Anti-tau antibody and use thereof | |
| BR112023016574A2 (pt) | Composições de anticorpo anti-tl1a e métodos de tratamento no pulmão | |
| CY1119976T1 (el) | Μιμητικα καλσιτονινης για την αντιμετωπιση ασθενειων και διαταραχων | |
| MX2022012525A (es) | Composiciones y metodos para el tratamiento de trastornos de agregacion de proteinas. | |
| EA202190310A1 (ru) | Белок для лечения воспалительных заболеваний | |
| EP4552693A3 (en) | Collagen peptide-based medicament compositions and devices and methods of production and use thereof | |
| MX2021010061A (es) | Proteínas de fusión fc con dominio extracelular de cd80 para tratar tumores negativos para pd-l1. | |
| BR112017004729A2 (pt) | processo de tratamento de doenças causadas por metástase óssea, medicamentos para as mesmas e processo de previsão do resultado clínico de tratamento de doenças causadas por metástase óssea | |
| BR112012026999A2 (pt) | peptídeo de caseína para uso no tratamento de infecções uterinas. | |
| BR112022004475A2 (pt) | Proteínas de fusão nkg2d e usos das mesmas | |
| BR112023022999A2 (pt) | Fusões peptídeo-fc para tratar distúrbios amiloides | |
| BR112023022624A2 (pt) | Composições e métodos para modular distúrbios e condições mamárias | |
| MX2024009890A (es) | Factores terapeuticos para el tratamiento de enfermedades poliglutaminicas | |
| Fujita et al. | HSP90 limits thrombin‑stimulated IL‑6 synthesis in osteoblast‑like MC3T3‑E1 cells: Regulation of p38 MAPK | |
| BR112022011976A2 (pt) | Composição para tratar ou prevenir uma alergia ou reação alérgica | |
| MX380750B (es) | Composición farmacéutica para tratar y/o prevenir el cáncer. | |
| CL2023001183A1 (es) | Proteínas de fusión para el tratamiento de enfermedades | |
| BR112015020253A2 (pt) | formulações e métodos para produção aumentada de proteína recombinante | |
| BR112022027124A2 (pt) | Formulações para promover a hidratação e métodos de uso das mesmas | |
| BR112014024398A2 (pt) | composição derivada de osteoprotegerina e uso desta | |
| EA202092963A1 (ru) | Новый белок с противовоспалительными свойствами |